文献速递神经儿科影像介入DSA

儿童症状性颅内静脉窦血栓血管内治疗的安全性与疗效

Safety and efficacy of endovascular treatment in symptomatic pediatric cerebral venous sinus thrombosis.
PubMed 文献 · Neuroradiology · 2026-10-02

该单中心回顾性研究纳入45例接受血管内治疗的儿童颅内静脉窦血栓患者,平均年龄14.8岁,88.9%为多窦血栓,31.1%伴脑实质出血。治疗采用单纯溶栓、单纯取栓或联合治疗,中位尿激酶剂量为每日13000 U/kg持续5-7天。中位随访68个月,所有患者均获得良好功能预后,提示血管内治疗是重症儿童CVST的有价值挽救选择。

要点

  • 儿童CVST血管内治疗适用于有严重神经症状的挽救性治疗。
  • 尿激酶剂量需个体化,中位每日13000 U/kg持续5-7天。
  • 术后并发症包括静脉窦穿孔和症状性颅内出血,需警惕。

关键影像表现/征象

  • 88.9%患者表现为多窦血栓,31.1%伴有脑实质出血。
  • 主要临床表现为头痛(82.2%)和意识障碍(37.8%)。
  • 中位AVOIS评分从基线5分降至出院时2分。
  • 术中发生2例静脉窦穿孔,1例症状性颅内出血。

诊断标准与关键数值

  • 治疗策略包括单纯溶栓(22.2%)、单纯取栓(37.8%)和联合治疗(40.0%)。
  • 中位每日个体化尿激酶剂量为13000 U/kg,持续5-7天。

临床应用与阅片要点

  • 对儿童CVST伴严重神经症状可考虑血管内治疗作为挽救措施。
  • 溶栓时尿激酶剂量应个体化,可联合或不联合机械取栓。
  • 术中需警惕静脉窦穿孔,术后需监测症状性颅内出血。

局限性

  • 单中心回顾性研究,样本量有限(45例),无对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Current guidelines recommend anticoagulation as the first-line treatment for pediatric cerebral venous sinus thrombosis (CVST), while the application, safety, and standardized regimen of endovascular treatment (EVT) in children remain controversial. This study aimed to evaluate the safety and efficacy of EVT for pediatric CVST and summarize the individualized endovascular strategy of thrombolysis and thrombectomy.

METHODS: A retrospective analysis was performed on pediatric patients (aged < 18 years) who received EVT for CVST at a single comprehensive medical center from March 2013 to November 2024. Baseline clinical data, imaging characteristics, procedural methods, perioperative complications, and follow-up outcomes were collected and analyzed.

RESULTS: A total of 45 pediatric CVST patients were enrolled, with a mean age of 14.8 years. The main clinical manifestations included headache (82.2%) and impaired consciousness (37.8%), and 88.9% of patients presented with multi-sinus thrombosis, accompanied by parenchymal hemorrhage in 31.1% of cases. The treatment strategies included simple thrombolysis (22.2%), simple thrombectomy (37.8%), and combined therapy (40.0%). The median daily individualized urokinase dose was 13,000 U/kg for 5-7 days. The median AVOIS score decreased from 5 at baseline to 2 at discharge. Two cases of intraoperative venous sinus perforation and one case of symptomatic intracranial hemorrhage were observed. At a median follow-up of 68 months, all patients achieved favorable functional outcomes.

CONCLUSION: Endovascular treatment represents a valuable rescue option for pediatric CVST patients with severe neurological symptoms. The dose of urokinase should be individualized during thrombolysis with or without mechanical thrombectomy.

来源:Neuroradiology,查看原文。版权归原作者所有。

引用

  1. Li J, Wang C, Liu K, et al. Safety and efficacy of endovascular treatment in symptomatic pediatric cerebral venous sinus thrombosis. Neuroradiology. 2026. PMID: 42825816. doi:10.1007/s00234-026-04196-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。